Merrimack Pharmaceuticals Overview

  • Founded
  • 1993

Founded
  • Status
  • Public

  • Employees
  • 27

Employees
  • Stock Symbol
  • MACK

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $4.27

  • (As of Monday Closing)

Merrimack Pharmaceuticals General Information

Description

Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Delivery
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • One Broadway
  • 14th floor
  • Cambridge, MA 02142
  • United States
+1 (617) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Merrimack Pharmaceuticals Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$4.27 $4.34 $3.66 - $7.41 $57.3M 13.4M 27.4K -$0.14

Merrimack Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 70,617 37,876 76,376 21,235
Revenue 0 0 0 0
EBITDA (1,888) (2,472) (3,064) (19,761)
Net Income (1,891) (2,455) (3,028) (17,332)
Total Assets 14,639 14,749 16,776 20,082
Total Debt 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Merrimack Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Merrimack Pharmaceuticals‘s full profile, request access.

Request a free trial

Merrimack Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicin
Drug Delivery
Cambridge, MA
27 As of 2018
00000
0000 0000-00-00
00000000 00000

000000

r incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ul
0000 000000000
Durham, NC
00 As of 0000
000.00
000000000 000.00

000000

tation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehender
0000000000000
Cambridge, MA
000 As of 0000
00000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Merrimack Pharmaceuticals Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Icagen Corporation Durham, NC 00 000.00 000000000 000.00
000000 00000000000 Corporation Cambridge, MA 000 00000 000000 - 000 00000
0000000 000000 Formerly VC-backed New York, NY 000 00000 00000000 00000
0000000 Formerly VC-backed Heidelberg, Germany 000 00000 000000000 00000
0000000 0000000000 Formerly VC-backed Cambridge, MA 00 00000 000000000 00000
You’re viewing 5 of 30 competitors. Get the full list »

Merrimack Pharmaceuticals Patents

Merrimack Pharmaceuticals Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3131953-A1 Anti-tnfr2 antibodies and uses thereof Pending 01-Mar-2019 00000000000
EP-3930846-A1 Anti-tnfr2 antibodies and uses thereof Pending 01-Mar-2019 00000000000
AU-2019342017-A1 Anti-tnfr2 antibodies and uses thereof Pending 18-Sep-2018 00000000000
CA-3153959-A1 Anti-tnfr2 antibodies and uses thereof Pending 18-Sep-2018 00000000000
US-20210371537-A1 Anti-tnfr2 antibodies and uses thereof Pending 18-Sep-2018 C07K16/2878
To view Merrimack Pharmaceuticals’s complete patent history, request access »

Merrimack Pharmaceuticals Executive Team (15)

Name Title Board Seat Contact Info
Tim Surgenor Head, Investor Relations
Gary Crocker Chief Executive Officer & Chief Financial Officer, Finance
You’re viewing 2 of 15 executive team members. Get the full list »

Merrimack Pharmaceuticals Board Members (14)

Name Representing Role Since
Eric Andersen Self Board Member 000 0000
James Dresser Self Board Member 000 0000
Noah Levy Self Board Member 000 0000
Russell Ray Merrimack Pharmaceuticals Board Member 000 0000
Ulrik Nielsen Ph.D Merrimack Pharmaceuticals Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Merrimack Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Merrimack Pharmaceuticals Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 000000 07-Dec-2009 0000000000 00.00 Drug Delivery
To view Merrimack Pharmaceuticals’s complete acquisitions history, request access »